SpecimenSEQ™ FFPE Inventory

The SpecimenSeq™ FPPE inventory report contains:

  • >22,000 detections of 552 specific genes across 16 oncology indications and 702 unique patients. Each FFPE biospecimen is ethically collected from treatment naive cancer patients.
 

Inventory Request Submission:

  1. Download and review the inventory report.
  2. Highlight your samples of interest and save the report.
  3. Submit the saved inventory report file via the contact form linked below, along with any additional details or requests.

Conduct smarter oncology R&D faster with SpecimenSEQ™

Overview:

Bridging a deep understanding of molecular profiles is critical to developing innovative precision medicine tools in oncology. SpecimenSeq makes this challenge easier for targeted oncology developers by delivering access to ethically collected biospecimens that are comprehensively annotated by genomic and pathological characteristics.

Image

SpecimenSeq™

Deliverables &
Characterization

Standalone FFPE

 
Biospecimen FormatQuantityCharacterization reports
FFPE1• Clinical information and pathology report
• Key variants report

NGS Characterization Panels:

Oncomine Focus Assay

The Oncomine Focus Assay is a targeted, multi-biomarker assay that enables detection of hotspots, SNVs, indels, CNVs, and gene fusions from DNA and RNA in a single workflow. View the full list of genes and fusions in this panel via the button below.

TruSight Oncology 500

TruSight Oncology 500 is a NGS assay that enables comprehensive genomic profiling of tumor samples. It supports identification of all relevant DNA and RNA variants implicated in various solid tumor types. View more details about this panel via the button below.

Additional characteristics are available through our expert, integrated service laboratories.

Image

IHC Services

Applications:

Image

Biomarker
Discovery

Verification of the presence of biomarker targets in your populations of interest

Image

Assessing
Mutations

Confirmation of driver mutations and other clinically relevant genomic variants across FFPE samples

Image

Oncology
Therapeutics

Acceleration of timelines for identifying responders versus non-responders and efficacy evaluations for new cancer therapies

To propel your projects with The Power of Discovery.™

Contact Us Today

Let us know about your project!

Image